Goodwin's global and fully integrated life sciences practice guided clients through transformative transactions, strategic partnerships, and innovative deals at every stage of their life cycle. This Year in Review celebrates our clients’ creativity and accomplishments, as well as our collaboration with industry leaders who continue to push the boundaries of science and medicine. Looking ahead, we remain steadfast in our commitment to guiding and supporting our clients as they chart new paths in the evolving life sciences landscape in 2025.
By The Numbers
Our Global Recognition
Notable Deals
Counsel to CRISPR Therapeutics AG (Nasdaq: CRSP) in its $280 million registered direct offering.
Counsel to Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) on its definitive agreement under which ONO Pharmaceutical Co., Ltd. (ONO) will acquire Deciphera for $25.60 per share in cash, which represents a total equity value of $2.4 billion.
Counsel to Prime Medicine, Inc. (Nasdaq: PRME) in its $110 million upfront, up to $3.5 billion strategic research collaboration and license agreement with Bristol-Myers Squibb.
Counsel to Biotheus in its $800 million acquisition by BioNTech SE (Nasdaq: BNTX, “BioNTech”).
Counsel to Avery Denninson on its definitive agreement to be acquired by Kyowa Kirin Co., Ltd. Kyowa Kirin acquired Orchard Therapeutics for $16.00 per American Depositary Share (ADS) in cash (approximately $387.4 million).
Counsel to Akero Therapeutics, Inc. (Nasdaq: AKRO) in its upsized public follow-on offering of 12,650,000 shares of its common stock, for gross proceeds of approximately $366.9 million.
Counsel to Kymera Therapeutics, Inc. (Nasdaq: KYMR) in its upsized underwritten follow-on public offering of $316.2 million.
Regulatory Initiatives
Rare Disease Initiative
Inflation Reduction Act
Laboratory Developed Tests
A Look Ahead in Life Sciences 2025
